Responses
Original research
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China
Compose a Response to This Article
Other responses
No responses have been published for this article.